What is he best known for?
The fields of study he is best known for:
His scientific interests lie mostly in Biochemistry, Molecular biology, Peptide sequence, Glucocerebrosidase and Protein subunit.
His studies in Complementary DNA, Amino acid, Sphingolipid Activator Proteins, Prosaposin and Molecular mass are all subfields of Biochemistry research.
His Molecular biology study combines topics in areas such as Protein primary structure, Ms analysis, Sample preparation, Analytical chemistry and Proteomics.
The concepts of his Peptide sequence study are interwoven with issues in Metabolite, Angiotensin II, Binding protein and Structural gene.
His Glucocerebrosidase research integrates issues from Gaucher's disease, Allele, Null allele and Genotype.
His Protein subunit research incorporates themes from Cerebral cortex, Alpha-2 adrenergic receptor, Nucleic acid and GABAA receptor.
His most cited work include:
- A mutation in the human glucocerebrosidase gene in neuronopathic Gaucher's disease. (266 citations)
- Animal model of Gaucher's disease from targeted disruption of the mouse glucocerebrosidase gene. (255 citations)
- Enteroaggregative Escherichia coli heat-stable enterotoxin 1 represents another subfamily of E. coli heat-stable toxin (234 citations)
What are the main themes of his work throughout his whole career to date?
Brian M. Martin mostly deals with Biochemistry, Molecular biology, Optics, Peptide sequence and Resist.
His Molecular biology research is multidisciplinary, incorporating elements of Nucleic acid sequence, Complementary DNA, Molecular cloning, Angiotensin II and Transcription.
His Optics study incorporates themes from Reticle and Wafer.
In his research, Amyloidosis is intimately related to Antibody, which falls under the overarching field of Peptide sequence.
Brian M. Martin interconnects Optoelectronics and Photolithography in the investigation of issues within Resist.
His Glucocerebrosidase research incorporates elements of Gaucher's disease and Immunology.
He most often published in these fields:
- Biochemistry (35.71%)
- Molecular biology (27.55%)
- Optics (17.86%)
What were the highlights of his more recent work (between 2002-2016)?
- Biochemistry (35.71%)
- Pathology (7.14%)
- Amyloidosis (4.08%)
In recent papers he was focusing on the following fields of study:
Brian M. Martin mainly focuses on Biochemistry, Pathology, Amyloidosis, Immunology and Enzyme.
His Biochemistry study frequently links to other fields, such as Chromatography.
His studies in Chromatography integrate themes in fields like Molecular biology, Proteomics and Peptide.
His Amyloidosis study integrates concerns from other disciplines, such as Immunohistochemistry, Immunoglobulin light chain, Antibody and Amyloid.
His Immunohistochemistry research focuses on Amyloid and how it connects with Peptide sequence.
His biological study spans a wide range of topics, including Progressive myoclonus epilepsy, Null allele and Myoclonic epilepsy.
Between 2002 and 2016, his most popular works were:
- Enrichment of low molecular weight fraction of serum for MS analysis of peptides associated with hepatocellular carcinoma (113 citations)
- Myoclonic epilepsy in Gaucher disease: genotype-phenotype insights from a rare patient subgroup. (95 citations)
- Nitration and inactivation of IDO by peroxynitrite. (62 citations)
In his most recent research, the most cited papers focused on:
The scientist’s investigation covers issues in Biochemistry, Peptide, Proteomics, Pathology and Biomarker.
His work blends Biochemistry and SNARE complex studies together.
His Peptide study incorporates themes from Molecular biology, Chromatography, Fibrinogen and Analytical chemistry.
He combines subjects such as Ms analysis, Sample preparation, Hepatocellular carcinoma, Melanoma and Biomarker discovery with his study of Molecular biology.
The concepts of his Analytical chemistry study are interwoven with issues in Peptide sequence and Alpha globulin.
His Pathology research is multidisciplinary, incorporating elements of Allele, Genotype and Myoclonic epilepsy.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
